Articles Tagged With:
-
Internal Medicine Alert - Full February 15, 2014 Issue in PDF
-
New Oral Anticoagulants Poised to Alter Approach to AF
-
What Medical Condition Does this Patient Have?
-
Dapagliflozin Tablets (Farxiga)
A second sodium-glucose cotransporter 2 (sglt2) inhibitor has been approved for the treatment of adults with type 2 diabetes mellitus. These agents increase glucose secretion by inhibiting reabsorption in the kidney. Renal glucose threshold can be lowered to 70-90 mg/dL from a norm of 240 mg/dL in patients with diabetes. Dapagliflozin follows canagliflozin as the second SGLT2 approved and is marketed by Bristol-Myers Squibb and AstraZeneca as Farxiga. -
Effect of Vitamin E and Memantine in Alzheimer's Disease
Among patients with mild-to-moderate Alzheimer's disease, 2000 IU/d of vitamin E resulted in a slower functional decline and a decrease in the caregiver burden. -
Spironolactone for Heart Failure
The authors concluded that in a diverse, community-based population with new systolic heart failure, spironolactone did not reduce death or hospitalization, but did increase the incidence of hyperkalemia. -
Influenza
Influenza is possibly the most widespread and well known of infectious diseases. Seasonal epidemics can be found on all continents, and no age segment of the population is untouched. -
Emergency Medicine Reports - Full January 12, 2014 Issue in PDF
-
Heavy lifting still brings toll of injuries
MSD goal: Reduce the rate of injury and illness cases involving days away from work due to overexertion or repetitive motion by 10% by 2020. -
Is Atrial Fibrillation Associated with Silent Cerebral Emboli?